| Radiopharma | Manufacture and supply of radiopharmaceutical diagnostics and therapeutics with a network of 45 US radiopharmacies. | Strong proprietary technology (Ruby-Fill), extensive US radiopharmacy network, regulatory approvals. | Hospitals, nuclear medicine clinics, and radiopharmacies (B2B). | Proprietary PET imaging generators and novel radiotherapeutics. | 3388 | 45 | Product sales, supply contracts, and service agreements in North American markets. | Contractual supply agreements and product sales. | Innovation in PET imaging and therapeutic radiopharmaceuticals, expanding radiopharmacy network. | Ruby-Fill Cardiac PET Generator, HICON Sodium Iodide I-131 |
| Allergy Immunotherapy | Treatment products and diagnostic devices for allergy immunotherapy and venom desensitization. | Sole supplier of venom therapy in North America with a legacy brand and stable customer base. | Allergists, ENT physicians, and specialized clinics (B2B). | Venom immunotherapy products. | 714 | 10 | Product sales primarily in the US and Canada allergic immunotherapy markets. | Direct sales and distribution agreements. | Increasing allergy prevalence and demand for immunotherapy treatments. | HollisterStier allergy and venom extracts |
| Contract Development and Manufacturing | Contract manufacturing of sterile injectables, lyophilization and custom injectable fill-finish services. | US and Canadian FDA approved manufacturing sites with customer trust and BARDA funding. | Global pharmaceutical companies and biotech firms (B2B). | Specialized injectable drug product manufacturing. | 1353 | 17 | Contract manufacturing fees from pharma innovators and generic companies. | Long-term contracts and service agreements. | Rising biologics pipeline, supply consolidation and increased regulatory demand for sterile manufacturing. | Jubilant HollisterStier sterile injectables |
| Contract Research, Development & Manufacturing Organisation (CRDMO) | Integrated drug discovery, medicinal chemistry, biology, and early CDMO services for pharmaceutical R&D. | World-class research centers in India and France with strong pharma partnerships. | Pharma and biotech companies (B2B). | Integrated drug discovery platforms and biologics capabilities. | 1173 | 16 | Fee-for-service and full time equivalent (FTE) contracts with pharma clients globally. | Subscription and project-based fee models. | Increased outsourcing of R&D and drug discovery, Biosecure Act encouraging US market expansion. | Jubilant Biosys drug discovery services |
| Generics | Development, manufacturing, and distribution of generic solid dosage forms for global markets. | Regulatory compliant manufacturing sites with established customer relationships. | Wholesalers, pharmacies, and hospitals (B2B/B2C). | Selected branded generics and chronic specialty areas. | 685 | 12 | Sales of generic products in regulated and emerging markets. | Direct sales and supply agreements. | Portfolio expansion, regulatory approvals, and margin improvements in key markets. | Jubilant Cadista Pharmaceuticals Inc. formulations |
| Proprietary Novel Drugs | Development of precision oral medicines targeting oncology and autoimmune diseases. | Advanced discovery engine with partnerships and orphan drug designations. | Pharmaceutical partners and patients (B2B/B2C). | Innovative targeted therapies. | 0 | 0 | Currently investment phase; future potential from licensing and commercialization. | Licensing revenue and potential product sales. | Clinical trial progress and partner collaborations. | JBI-802, JBI-778 clinical-stage molecules |
